HPV vaccine acceptance in Latin America and the Caribbean: a systematic review and meta-analysis

Human Papillomavirus (HPV) infection poses a significant health burden in Latin America and the Caribbean (LAC), leading to various conditions from benign to malignant, including cervical, anal, and oropharyngeal cancers. This systematic review encompassed 24 studies with a total of 14,466 participants, exploring HPV vaccine acceptance in the region. It was conducted using the following databases: PubMed, Scopus, Ovid Medline, and Web of Science. The review reveals an 84% prevalence of HPV vaccine acceptance in the LAC. Factors influencing acceptance include education, income levels, and vaccine safety concerns. Peru and Honduras exhibited the highest acceptance rates, while the coronavirus disease 2019 (COVID-19) pandemic contributed to declining acceptance post-2019. The importance of educational campaigns and healthcare recommendations in promoting vaccine acceptance is highlighted, along with the impact of reduced vaccination access during the pandemic. This study underscores the critical role of ongoing educational initiatives and accessible healthcare in maintaining high HPV vaccine acceptance rates in LAC. Addressing the reduced acceptance during the pandemic is pivotal for reinstating effective vaccination programs. Findings emphasize the need of sustained efforts to ensure widespread vaccine acceptance, thereby mitigating the burden of HPV-related diseases in the region.